InsiderClue
Stocks · Health care · Pharmaceutical Preparations

Grace Therapeutics, Inc.

GRCE Clue Score35
United States Fiscal year ends March CIK 0001444192
$2.08 +1.96% Close, 9 Oct 2026
Alert on the numbers Alert on insider trades
Price $2.08 −31.13% Close, 9 Oct 2026

Closing prices at the end of each trading day, from 8 Oct 2024. Not a live quote. Adjusted for share splits, so the line has no step at a split; dividends are not added back.

Revenue and profit

What the business sells, and what is left of it. Point at a year for the detail.
RevenueOperating incomeNet income
Fiscal year 2017Operating income−11.2Net income−11.2Fiscal year 2018Operating income−19.7Net income−21.5Fiscal year 2019Operating income−34.4Net income−39.4Fiscal year 2020Operating income−24.4Net income−25.5Fiscal year 2021Revenue0.2Operating income−16.4Net income−19.7Fiscal year 2022Revenue100.0 +50,920.4%Operating income−15.6Net income−9.8EPS, diluted−0.27Fiscal year 2023Operating income−52.2Net income−42.4EPS, diluted−5.71Fiscal year 2024Operating income−12.9Net income−12.9EPS, diluted−1.35Fiscal year 2025Operating income−16.7Net income−9.6EPS, diluted−0.79Fiscal year 2026Operating income−11.1Net income−7.8EPS, diluted−0.47
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Revenue n/a n/a n/a n/a 0.2 100.0 n/a n/a n/a n/a
Growth +50,920.4%
Operating income −11.2 −19.7 −34.4 −24.4 −16.4 −15.6 −52.2 −12.9 −16.7 −11.1
Net income −11.2 −21.5 −39.4 −25.5 −19.7 −9.8 −42.4 −12.9 −9.6 −7.8
Growth
EPS, diluted n/a n/a n/a n/a n/a −0.27 −5.71 −1.35 −0.79 −0.47

Margins

How much of each dollar of revenue it keeps. Point at a year for the detail.
Operating marginNet margin
Fiscal year 2017Fiscal year 2018Fiscal year 2019Fiscal year 2020Fiscal year 2021Operating margin−8,377.0%Net margin−10,039.8%Fiscal year 2022Operating margin−15.6%Net margin−9.8%Fiscal year 2023Fiscal year 2024Fiscal year 2025Fiscal year 2026
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Operating margin n/a n/a n/a n/a −8,377.0% −15.6% n/a n/a n/a n/a
Net margin n/a n/a n/a n/a −10,039.8% −9.8% n/a n/a n/a n/a

Cash flow

The cash the business makes, what it reinvests, and what it hands back. Point at a year for the detail.
Operating cash flowCapital expenditureFree cash flow
Fiscal year 2017Operating cash flow−7.0Capital expenditure−2.5Free cash flow−9.5Fiscal year 2018Operating cash flow−12.5Capital expenditure−0.5Free cash flow−13.0Fiscal year 2019Operating cash flow−32.5Capital expenditure−0.7Free cash flow−33.2Fiscal year 2020Operating cash flow−23.0Fiscal year 2021Operating cash flow−14.3Fiscal year 2022Operating cash flow−17.2Fiscal year 2023Operating cash flow−15.9Fiscal year 2024Operating cash flow−12.3Fiscal year 2025Operating cash flow−14.9Fiscal year 2026Operating cash flow−8.9
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Operating cash flow −7.0 −12.5 −32.5 −23.0 −14.3 −17.2 −15.9 −12.3 −14.9 −8.9
Capital expenditure −2.5 −0.5 −0.7 n/a n/a n/a n/a n/a n/a n/a
Free cash flow −9.5 −13.0 −33.2 n/a n/a n/a n/a n/a n/a n/a
Growth

Balance sheet

What it holds against what it owes, at each year end. Point at a year for the detail.
Cash
Fiscal year 2017Cash9.8Shareholders’ equity21.7Fiscal year 2018Cash8.2Shareholders’ equity7.2Fiscal year 2019Cash16.9Shareholders’ equity11.0Fiscal year 2020Cash14.2Shareholders’ equity13.0Fiscal year 2021Cash50.9Shareholders’ equity55.7Fiscal year 2022Cash30.3Shareholders’ equity108.3Fiscal year 2023Cash27.9Shareholders’ equity68.0Fiscal year 2024Cash23.0Shareholders’ equity61.7Fiscal year 2025Cash22.1Shareholders’ equity66.6Fiscal year 2026Cash17.0Shareholders’ equity63.9
FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025FY2026
Cash 9.8 8.2 16.9 14.2 50.9 30.3 27.9 23.0 22.1 17.0
Shareholders’ equity 21.7 7.2 11.0 13.0 55.7 108.3 68.0 61.7 66.6 63.9

In millions of USD, except per-share figures and ratios. Fiscal years, as last filed with the SEC.

Financial statements FY2026 · 10-K

Income statement

In millions of USD, except per-share figures; shares in millions. Fiscal years ending March, each column as last filed with the SEC.
Click a line to chart it
Fiscal year FY2017 28 Feb 2017 FY2017 31 Mar 2017 FY2018 31 Mar 2018 FY2019 31 Mar 2019 FY2020 31 Mar 2020 FY2021 31 Mar 2021 FY2022 31 Mar 2022 FY2023† 31 Mar 2023 FY2024 31 Mar 2024 FY2025 31 Mar 2025 FY2026 31 Mar 2026
Revenue and profit
n/a n/a n/a n/a n/a 0.2 100.0 n/a n/a n/a n/a
Growth +50,920.4%
n/a n/a n/a n/a n/a 0.1 0.0 n/a n/a n/a n/a
7.2 7.7 15.7 38.4 n/a n/a n/a n/a n/a n/a n/a
3.3 3.6 4.0 6.6 n/a n/a n/a n/a n/a n/a n/a
−10.5 −11.2 −19.7 −34.4 −24.4 −16.4 −15.6 −52.2 −12.9 −16.7 −11.1
Growth
n/a n/a n/a −39.4 −25.5 −19.7 −10.5 −52.0 −14.7 −12.8 −9.5
−0.1 −0.1 n/a 0.0 0.0 0.0 −0.6 −9.5 −1.8 −3.2 −1.7
−10.5 −11.2 −21.5 −39.4 −25.5 −19.7 −9.8 −42.4 −12.9 −9.6 −7.8
Growth
Per share
n/a n/a n/a n/a n/a n/a −0.27 −5.71 −1.35 −0.79 −0.47
n/a n/a n/a n/a n/a n/a −0.27 −5.71 −1.35 −0.79 −0.47
Growth
10.8 11.1 17.5 54.3 n/a n/a 36.8 7.4 9.5 12.1 16.5
n/a n/a n/a n/a n/a n/a 36.8 7.4 9.5 12.1 16.5
Growth −79.8% +28.2% +26.8% +36.6%

† The diluted share count jumps at 2023, so per-share figures either side of that column are not comparable. Usually a split, but the break lands on the restatement boundary rather than on the split date, because every column is that period’s latest filing.

Five years in brief

Worked out from the figures above, not from a press release
  • A net loss in 11 of 11 years on file.